Theralase Technologies Inc.

101 articles about Theralase Technologies Inc.

• Theralase Announces Warrant Extension

  9/30/2020

  Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, announces that the Company proposes to extend the expiry date of 3,157,059 share purchase warrants, all of which are exercisable at $0.50 per share.

• Theralase Provides Update on Voting Procedures for Shareholder Meeting

  9/24/2020

  Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations, provides clarification on how registered shareholders or duly appointed proxyholders who plan to attend the Company's virtual Annual General and Special Meeting at 4:30pm EDT can cast their vote at the Meeting.

• Theralase Provides Update on Bladder Cancer Study

  9/24/2020

  Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations, announced that McGill University Health Centre has re-commenced new patient enrollment and treatment in the Company's Phase II Non-Muscle Invasive Bladder Cancer clinical study.

• Theralase Amends the Company’s Standard By-Laws

  8/19/2020

  Theralase announced today that the board of directors of Theralase has approved amendments to the Company's standard by-laws.

• Theralase Signs Agreement with University of Manitoba to Commence Development of Coronavirus Vaccine and Therapy

  8/19/2020

  Theralase announced today that it has executed a Sponsored Research Agreement ("SRA") with the University of Manitoba ("UM") Medical Microbiology department to commence development of a coronavirus vaccine and therapy utilizing Theralase's patented and proprietary PDCs.

• Theralase Releases Quarterly Newsletter - Aug 17, 2020

  8/17/2020

  Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations has released the Company Quarterly Newsletter.

• Theralase Releases Quarterly Newsletter

  8/17/2020

  Theralase® Technologies Inc., a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and associated drug formulations has released the Company Quarterly Newsletter.

• Canadian Clinical Study Sites Re-Commence Bladder Cancer Study

  8/12/2020

  Theralase® Technologies Inc. ("Theralase" or "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and associated drug formulations, announced today that three out of four of its Canadian clinical study sites have re-commenced new patient enrollment and treatment in the Company's Phase II Non-Muscle Invasive Bladder Cance

• Theralase Reports on Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study ("Study II") Progress

  7/30/2020

  Results of the First 12 patients enrolled in the Phase II NMIBC Clinical Study Demonstrate a 58.3% Response 90 Days Post Initial Treatment

• Theralase Announces Management Information Circular and Annual General Meeting Postponement Due to COVID-19

  6/30/2020

  Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations intended to safely and effectively destroy various cancers announces that after careful consideration the Company has decided to postpone its management information circular and the Annual General Meeting ("AGM").

• Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment

  4/2/2019

  Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate a 66% Complete Response ("CR") at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post Treatment

• Theralase’s Phase IB Clinical Study to be Presented at the 17(th) International Photodynamic Association World Congress

  3/26/2019

  Theralase Technologies Inc. is pleased to announce that the results of the Phase Ib clinical study will be presented at the 17th International Photodynamic Association World Congress, to be held in Cambridge, Massachusetts from June 28th to July 4th, 2019.

• Theralase Technologies Inc. To Present At The Small-Cap Stars Spring Conference 2015 At Convene In Times Square New York On June 10

  6/4/2015

• Theralase Technologies Inc. Discovers Anti-Cancer Memory Response

  6/2/2014

• Tekmira Pharmaceuticals Corporation And Theralase Technologies Inc. Leaders in Innovative Drug Therapies

  4/3/2014

• Theralase Technologies Inc. CEO To Be Interviewed Today On Clear Channel Business Talk Radio DFW 1190AM

  3/12/2014

• Theralase Technologies Inc. Commences Small Animal Pre-Clinical Trials for Destruction of Cancer Cells

  11/9/2010

• Theralase Technologies Inc. Receives Popular Mechanics Magazine

  9/30/2010

• Theralase Technologies Inc. Welcomes Renowned Veterinarian to Medical & Scientific Advisory Board

  8/9/2010

• Theralase Technologies Inc. Starts Small Animal Cancer Therapy Trials

  6/8/2010